Journal of Ophthalmology
Volume 2015 (2015), Article ID 275435, 10 pages
http://dx.doi.org/10.1155/2015/275435

Review Article

Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases

Su Zhang, Hongwei Gu, and Nan Hu

Department of Ophthalmology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China

Received 27 February 2015; Accepted 19 May 2015

Academic Editor: Enrico Peiretti

Copyright © 2015 Su Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Peroxisome proliferator-activated receptor γ (PPAR γ), a member of the nuclear receptor superfamily, is a ligand-activated transcription factor that plays an important role in the control of a variety of physiological processes. The last decade has witnessed an increasing interest for the role played by the agonists of PPAR γ in antiangiogenesis, antifibrosis, anti-inflammation effects and in controlling oxidative stress response in various organs. As the pathologic mechanisms of major blinding diseases, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), keratitis, and optic neuropathy, often involve neoangiogenesis and inflammation- and oxidative stress-mediated cell death, evidences are accumulating on the potential benefits of PPAR γ to improve or prevent these vision threatening eye diseases. In this paper we describe what is known about the role of PPAR γ in the ocular pathophysiological processes and PPAR γ agonists as novel adjuvants in the treatment of eye diseases.

1. Introduction

Peroxisome proliferator-activated receptor γ (PPAR γ), a member of the nuclear receptor superfamily, is a ligand-activated transcription factor that plays an important role in the control of gene expression linked to a variety of physiological processes [1]. PPAR γ was first identified by homology cloning in Xenopus [2] and then in mammals [3] and mice [4]. It is most widely expressed in adipose tissue but is also expressed in immune/inflammatory cells (e.g., monocytes, macrophages), mucosa of the colon and cecum, skeletal muscle, heart, kidney, liver, lung, and the eye ball [5–8]. Similar to typical nuclear receptors, PPAR γ is comprised of distinct functional domains, including an N-terminal transactivation domain (AF1), a highly conserved DNA-binding domain (DBD), and a C-terminal ligand-binding domain (LBD) containing a ligand-dependent transactivation function (AF2) [9].

PPAR γ can regulate transcription by several mechanisms, including ligand-dependent transactivation, ligand-dependent transrepression, and ligand-independent repression. PPAR γ is activated by heterodimerization with the retinoid X receptor (RXR) into biologically active transcription factor and then binds to peroxisome proliferator response elements (PPREs), thereby acting as a transcriptional regulator [10, 11]. PPAR γ is also capable of regulating gene expression independently of binding to PPREs. PPAR γ possesses a large T-shaped ligand-binding pocket that enables interaction with a structurally diverse library of ligands [12]. A wide range of natural and synthetic compounds functioning as PPAR γ ligands have been identified (Table 1).

Table 1: Ligands for PPAR .

Ligand class
Compounds
References

Endogenous agonists
15d-PGJ2,
[122–125]

13-Hydroxyoctadecadienoic acid (13-HODE),
[122]

9-hydroxyoctadecadienoic acid (9-HODE),
[122]

15-hydroxyeicosatetraenoic acid (15-HETE),
[123]

nitrolinoleic acid
[126]

Synthetic agonists
Pioglitazone, troglitazone, rosiglitazone, ciglitazone, TZD18,
[127–129]

JTT-501, CDDO, SB-219994, SB-219993, GW2331, GW0072,
[130–133]

5-ASA, PAT5A, TAK-559, GW7845, GW1929, LG10074,
[122, 134–137]

indomethacin, ibuprofen, flufenamic acid, conjugated linoleic acid,
[123, 138–140]

L-764406, L-796449, LY-510929, LY-465608, AD-5061, AD-5075,
[141–144]

KRP-297/MK-0767, MCC555, ragaglitazar, farglitazar, diclofenac
[145–148]

Antagonists
GW9662, CDDO-Me, BADGE, PD068235, SR-202
[149, 150]

Endogenous ligands for PPAR γ include unsaturated and oxidized fatty acids, nitrated fatty acids, eicosanoids, and prostaglandins [13]. Thiazolidinediones (TZDs) including troglitazone, pioglitazone, and rosiglitazone are synthetic PPAR γ ligands with the efficacy to enhance insulin sensitivity in animals and humans [14, 15], and some of the TZDs are already in clinical use as insulin sensitizers in type 2 diabetic patients [16]. With more intensive investigations, the number of PPAR γ ligands continues to increase for their key role in regulating metabolic processes.

PPAR γ is involved in a range of distinct physiological processes including fat cell differentiation, glucose homeostasis, lipid metabolism, aging, and inflammatory and immune responses [1, 17–20]. Previous investigations have found that PPAR γ and its ligands have good antiangiogenesis and antifibrosis effects in various organs [21–24]. Furthermore, recent studies indicate that PPAR γ plays an important role in oxidative stress response. It may directly modulate activation of several antioxidants involved in oxidative stress and influence apoptotic or necrotic cell death [25]. In regard to the immune system, PPAR γ is found in monocytes, macrophages, T cells, and dendritic cells and has been identified as crucial regulator of inflammatory gene expression [26–31]. As the pathologic mechanisms of major blinding diseases, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), keratitis, and optic neuropathy, often involve neoangiogenesis and inflammation- and oxidative stress-mediated cell death, evidences are accumulating on the potential benefits of PPAR γ to improve or prevent these vision threatening eye diseases. However, there also several studies that reported the side effects of PPAR γ in some ocular diseases [32–37]. In this paper we describe what is known about the role of PPAR γ in the ocular pathophysiological processes and PPAR γ agonists as novel adjuvants in the treatment of eye diseases.

2. PPAR γ and Ocular Disease

2.1. PPAR γ and Ocular Surface Disease

2.1.1. PPAR γ and Corneal Neovascularization and Fibrosis

The cornea is an avascular tissue and must remain transparent to refract light properly. Corneal neovascularization and fibrosis often lead to loss of corneal transparency which is an important cause of blindness. Diseases associated with corneal neovascularization include inflammatory disorders, corneal graft rejection, infectious keratitis, traumatic and chemical insults, contact lens-related hypoxia, aniridia, and limbal stem cell deficiency [38]. As potential angiogenesis modulators [39, 40], PPAR γ ligands have a good inhibition of corneal neovascularization [6, 41–43]. In 1999, Xin et al. [6] first reported that administration of 15d-PGJ2 inhibited vascular endothelial cell growth factor- (VEGF-) induced angiogenesis in the rat cornea. Then, Usui et al. [41] found that telmisartan, a partial agonist of PPAR γ, significantly reduced vascularized area in mice cornea. Furthermore, telmisartan-induced inhibition of corneal neovascularization was partially reversed by the administration of GW9662 (a PPAR γ antagonist), indicating that the inhibitory effects were partially mediated through PPAR γ signaling. Sarayba et al. [43] randomly divide twenty-six adult male Sprague-Dawley rats into three groups. Each group received intrastromal polymer micropellets containing different doses and types of pioglitazone. The area and density of neovascularization were measured 7 days after pellet implantation. The result indicated that pioglitazone can effectively inhibit VEGF-induced corneal neovascularization. Recently, Uchiyama et al. [42] also demonstrated that the ophthalmic solution of the PPAR γ agonist could inhibit inflammation, decrease the fibrotic reaction, and prevent neovascularization in the cornea from the early phase after alkali burn injury. Corneal neovascularization is a complex process that includes degradation of basement membrane and proliferation, migration, and tube formation by endothelial cells [44]. Activation of PPAR γ suppresses endothelial cell differentiation into tube-like structures and represses growth factor-induced endothelial cell proliferation in vitro [6]. PPAR γ activation also inhibits the expression of at least three important genes in the angiogenic process, the VEGF receptors Flk/KDR, Flt-1, and the protease uPA [6]. In addition, PPAR γ can reduce the activity of angiogenesis by inhibiting inflammatory cytokines at the transcriptional level via suppression of the AP-1, NF-κB pathway [45]. These observations indicate some possible molecular mechanisms by which PPAR γ ligands mediate inhibition of corneal neovascularization. The TGFβ-induced differentiation of corneal keratocytes into myofibroblasts plays a critical role in corneal scarring. PPAR γ ligands have antifibrotic effects and have been studied as agents capable of inhibiting TGFβ-induced myofibroblast differentiation in cornea [46–49]. Using corneal fibroblasts cultured in vitro, Huxlin et al. [46] and Pan et al. [48] demonstrated that pioglitazone suppressed TGFβ-induced alpha smooth muscle actin (αSMA) expression, inhibited cell migration, contractility, matrix metalloproteinase (MMP) secretion, and extracellular matrix production. Electrophilic PPAR γ ligands, CDDO-Me and κ15d-PGJ2, were also able to inhibit corneal fibroblast to myofibroblast differentiation in vitro [47]. Viral transfection and overexpression of PPAR γ inhibited activation of ocular fibroblasts and macrophages in vitro and also reduced myofibroblast differentiation, upregulation of several cytokines and matrix metalloproteases, and macrophage/monocyte invasion in an alkali-burned mouse cornea [50]. Since viral transfection is not yet widely practiced clinically, several authors investigated the effects of topical PPAR γ ligands on corneal fibrosis [42, 46]. Topical application of rosiglitazone to cat eyes following laser ablation of the corneal stroma decreased αSMA expression, blocking myofibroblast differentiation, while allowing the epithelium and stroma to return to a normal thickness, restoring corneal shape, structure, and optical quality to near-normal levels [46]. The ophthalmic solution containing 0.1% pioglitazone hydrochloride significantly decreased the fibrotic reaction in the rat cornea after alkali burn injury [42]. All these evidences suggest that PPAR γ ligands may exert a direct antifibrosis effect to prevent the corneal scar formation.

2.1.2. PPAR γ and Conjunctiva Fibrosis

Conjunctival scarring potentially reduces filtration efficacy after glaucoma filtering surgery. Yamanaka and his fellows [51] found that PPAR γ gene transfer suppresses the fibrogenic reaction in human subconjunctival fibroblasts (hSCFs) as well as the injury-induced scarring of conjunctival tissue in mice. PPAR γ overexpression may reduce the expression of type I collagen, fibronectin, and connective tissue growth factor (CTGF) in cultured hSCFs. It may also suppress invasion of macrophages into the healing subconjunctival tissue and generation of myofibroblasts [51]. Consistent with this result, Fan [52] and his fellows reported that rosiglitazone can effectively attenuate activation of human Tenon’s fibroblasts (HTFs) induced by TGFβ1 without obvious toxicity. The possible mechanism might be that rosiglitazone interferes with TGFβ/Smad signaling pathway. Thus, PPAR γ and its agonists may represent a new strategy for inhibiting excessive bleb scarring in the conjunctiva after glaucoma surgery. Pterygium is a wing-like fibrovascular proliferation, of exposed bulbar conjunctival tissue, which encroaches onto the cornea. PPAR γ is positively expressed in pterygium specimens obtained from patients undergoing routine pterygium excision [53]. The role of PPAR γ as a potential therapeutic agent for pterygium was studied on cultured human pterygium fibroblasts (HPFs) in vitro. The results showed that PPAR γ agonists can significantly inhibit HPFs proliferation and induce apoptosis of HPFs in dose- and time-dependent manners [53, 54].

2.1.3. PPAR γ and Dry Eye

Recently, Chen et al. [55] reported that the PPAR γ expression in the conjunctiva of dry eye mice was downregulated, accompanied by increased contents of inflammatory cytokines, TNF-α and IL-1β. They also found that pioglitazone may activate PPAR γ to suppress the inflammatory progression, increase the tear fluid production, elevate the tear film stability, and reduce the damage to the ocular surface, exerting a therapeutic effect on dry eye. In cultured lacrimal gland acinar cells, pioglitazone can inhibit NO production, excessive synthesis of which may be detrimental to normal function of the lacrimal gland, suggesting that the use of PPAR γ agonist may provide an effective therapeutic intervention for the prevention of dry eye caused by decrease or lack of lacrimal gland secretion [56].

2.1.4. PPAR γ and Meibomian Gland Dysfunction (MGD)

Recently, Jester and Nien published a series of papers on PPAR γ and MGD [7, 57, 58]. Their studies have shown that mouse and human meibomian glands undergo specific age-related changes, including decreased acinar cell proliferation, decreased meibomian gland size, and increased inflammatory cell infiltration. These changes occur concurrently with altered PPAR γ localization from cytoplasmic-vesicular/nuclei of acinar cells in young mice and humans to nuclei in older individuals. Meibomian glands express PPAR γ in lipid synthesizing cells and PPAR γ is a biomolecular marker for meibocyte differentiation. By analyzing eyelid tissue from 36 patients (age range, 18–95 years) who underwent canthoplasty procedures, they found that the degree of MGD dropout was significantly correlated with nuclear PPAR γ staining, indicating that age-related MGD may involve altered PPAR γ localization. Based on these findings, Jester et al. proposed that age-related MGD involves altered regulation of PPAR γ gene that may lead to decreased meibocyte differentiation, acinar atrophy, decreased lipid synthesis, and the development of hyposecretory MGD.

2.2. PPAR γ and Retinal Disease

2.2.1. PPAR γ and AMD

Age-related macular degeneration (AMD) is a degenerative disease of the macula which results primarily in loss of central vision [59]. The disease can be classified into a dry or nonexudative form (geographic atrophy) and a wet or exudative form (neovascular AMD). There is a growing body of research demonstrating that PPAR γ may be involved in various chemical pathways associated with AMD. PPAR γ is constitutively expressed in normal neuroretina and retinal pigmented epithelial (RPE) cells of mice and humans. However, the expression of PPAR γ is significantly higher than normal in both Ccl2−/−/Cx3cr1−/− mice (an AMD model) and AMD patients [60]. The exudative form of AMD, characterized by choroidal neovascularization (CNV), is thought to be responsible for most of the cases of severe visual loss in this disease. Murata et al. [61] have demonstrated that PPAR γ ligands, troglitazone or rosiglitazone, significantly inhibited VEGF-induced proliferation and migration of RPE and choroidal endothelial cells and choroidal angiogenesis in vitro. In the eyes of rat and monkeys in which CNV was induced by laser photocoagulation, this group also showed that intravitreal injection of troglitazone dramatically inhibited the percentage of lesions as well as leakage per lesion. Increased intake of omega-3 long-chain polyunsaturated fatty acids (ω-3 LCPUFAs), endogenous agonists of PPARs [62], is associated with attenuation of pathologic retinal and choroidal angiogenesis [63]. More recently, SanGiovanni and his colleagues found that DNA sequence variation in PPAR γ coactivator 1 alpha, a gene encoding a coactivator of the ω-3 LCPUFAs-sensing PPAR-retinoid X receptor (RXR) transcription complex, may influence neovascularization in AMD [64]. The results suggest that multiple constituents (ligands and transcriptional coactivators) of the PPAR-RXR system may influence pathogenic processes in CNV. There is evidence that dysfunction of RPE around macula area may be responsible for the development of AMD [58, 65]. One of the most important functions of RPE is phagocytic uptake and degradation of photoreceptor outer segments [64]. A study showed that specific phagocytosis of photoreceptor outer segments by RPE cells selectively activates expression of PPAR γ, suggesting that PPAR γ may play an important role in the photoreceptor renewal process [66]. Oxidative stress is a major risk factor causing RPE cell degeneration. A number of studies have shown that RPE might be the prime target for oxidative stress and PPAR γ is implicated in the oxidative stress response [25]. In cultured human primary RPE cells and/or ARPE-19 cells, troglitazone and 15d-PGJ2 can protect cells from oxidative stress induced by t-butylhydroperoxide or H₂O₂ [67–69]. Other PPAR γ agonists, rosiglitazone [67, 69], pioglitazone [69], ciglitazone [68], AGN195037 [67], azelaoyl PAF [68], LY171883 [68], and WY14643 [68], however, are not effective. To determine whether the cytoprotective effects of troglitazone and 15d-PGJ2 were mediated by PPAR γ, PPAR γ expression was knocked down using RNA interference. In the cells lacking PPAR γ expression, troglitazone’s protective effect was greatly blocked [69], while 15d-PGJ2’s protective activity was not affected [67]. These results indicate that the cytoprotective effect of troglitazone is mediated by PPAR γ but the effect of 15d-PGJ2 is independent of PPAR γ activity, and PPAR γ agonists can have differential effects on RPE survival in response to oxidative stress.

2.2.2. PPAR γ and DR

Diabetic retinopathy (DR) remains as the leading cause of blindness among working age individuals in developed countries, which is one of the most common microvascular complications of diabetes. TZDs, synthetic PPAR γ agonists, in addition to increasing insulin sensitivity and regulating lipid metabolism [70, 71], may also exert anti-inflammatory, antiatherogenic, neuroprotective, and antioxidative effects [72–75]. Because of these beneficial effects, they may have therapeutic potential in diabetic microvascular complications such as DR.

In vitro and in vivo experiments have demonstrated that TZDs may provide retinal microcirculatory stability [76–78], attenuate pathological retinal microvessel formation [79], inhibit the fibrotic change of RPE cells [80], and also prevent retinal neuronal damage [81] in diabetic and ischemic retinopathy. Recently, a study showed that pioglitazone might improve impaired insulin signaling in the diabetic rat retina [82]. Murata et al. [83] illustrated that TZDs may have the potential to inhibit the progression of DR. In vitro, they found that troglitazone and rosiglitazone could inhibit the proliferation of retinal endothelial cell and tube formation induced by VEGF. Meanwhile, using the oxygen-induced ischemia model of retinal neovascularization in neonatal mice they showed that intravitreous injection of troglitazone and rosiglitazone could inhibit development of retinal neovascularization. To support these experimental evidences, a clinical study showed that the progression from nonproliferative DR to proliferative DR over 3 years occurred in 19.2% in the rosiglitazone group and 47.4% in the control group, suggesting that rosiglitazone may delay the onset of proliferative DR [84]. However, there are some adverse effects of TZDs that have been reported. Several clinical studies showed that TZDs increased the risk of macular edema [32–35]. Other studies found that administration of pioglitazone [36] and troglitazone [37] significantly increased plasma VEGF expression in diabetic patients which increased risk of diabetic macular oedema (DME) and promoted the progression of DR. The relationship between TZDs and DME is still controversial. Some authors reported that they did not detect fluid retention in the macula or subclinical DME under TZDs treatment [85, 86]. Further clinical and experimental studies are urgently required.

Apart from these synthetic PPAR γ agonists, herbal and traditional natural medicines, such as Astragalus membranaceus, Pueraria thomsonii [87], Swietenia mahagoni [69], Korean red ginseng [59], Dan-shao-hua-xian formula [88–90], and Turmeric [91–94], have shown the potential effect in the modulation of DR through PPAR γ activation. Tom Huang’s group summarized the current studies on herbal or traditional medicine associated with PPAR γ activation and the possible mechanisms relevant to the management of DR [8]. They confirmed that plant-derived PPAR γ activators could provide an alternative or combination therapy to prevent or delay the progression of DR.

2.2.3. PPAR γ and Retinal Neuroprotection

It is well known that PPAR γ has neuroprotective effects in central nervous system (CNS) [95]. Several studies indicated that PPAR γ agonists could prevent or attenuate the process of neurodegenerative diseases in Parkinson’s disease [96], Alzheimer’s disease [97], and amyotrophic lateral sclerosis [98]. Various PPAR γ agonists (e.g., troglitazone, rosiglitazone, and pioglitazone) have shown beneficial effects in animal models of cerebral ischemia/reperfusion injury, ischemic stroke, intracerebral hemorrhage, traumatic brain injury, and spinal cord injury by attenuating neuronal cell death in the injured CNS [99–103]. Using a rat model of optic nerve crush (ONC), our research group demonstrated that PPAR γ activation is beneficial in retinal neuroprotection [104]. We found that PPAR γ was upregulated in rat retina after ONC and most of PPAR γ immunoreactive cells colocalized with Müller cells. Intraperitoneal injection of pioglitazone significantly enhanced the number of surviving retinal ganglion cells (RGCs) and inhibited RGCs apoptosis induced by ONC. But these neuroprotective effects were abrogated in the presence of PPAR γ antagonist GW9662. In addition, pioglitazone attenuated Müller cell activation after ONC. In coincidence with our results, Zhang et al. reported the protective effect of pioglitazone on the rat retina after ischemia/reperfusion injury [105]. They found that pioglitazone could inhibit activation of the glia cells, prevent cell apoptosis, and protect the retina from subsequent cellular damage caused by the retinal I/R. In vitro, other two PPAR γ ligands, 15d-PGJ2 and troglitazone, also appeared to protect RGC-5 cells against glutamate-induced cytotoxicity. To understand the more specific mechanisms of PPAR γ-based neuroprotection in retina, future studies would be needed.

2.3. PPAR γ and Other Ocular Diseases

PPAR γ has been found to be associated with thyroid eye disease (TED), Graves’ ophthalmopathy (GO), or thyroid-associated orbitopathy (TAO), an autoimmune eye condition that is often seen with thyroid disease. The expression of PPAR γ was significantly increased in orbital tissue samples from patients with GO compared with normal orbital tissue [106, 107]. PPAR γ may play divergent roles in the process of the disease, both attenuating and promoting disease progression. PPAR γ activation is critical to adipogenesis, making it a potential culprit in the pathological fat accumulation associated with TED or GO [108]. Downregulation of PPAR γ could reduce adipogenesis [109]. Starkey reported that a male type 2 diabetic patient, treated with pioglitazone, experienced rapid exacerbation of his TED, which had been stable and inactive for more than 2 yr. In his in vitro experiments, by isolating and culturing preadipocytes from TED orbits, he demonstrated that the PPAR γ agonists resulted in a 2- to 13-fold increase, and a PPAR γ antagonist produced a 2- to 7-fold reduction in adipogenesis [110]. Consistent with this finding, sodium diclofenac, another antagonist of PPAR γ, also appeared to have efficacy in the treatment of GO [111]. However, PPAR γ also has anti-inflammatory activity. Pioglitazone and rosiglitazone have been found to inhibit TGFβ-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts, suggesting that they could inhibit intense inflammation and might be useful in treating TED [112]. Thus, if PPAR γ function is to be targeted as a TED therapeutic, PPAR γ modulators with selective activities would be required.

PPAR γ expression has been already studied in several tumors, and most studies implicate a protective effect of PPAR γ activation in tumors [113–116]. A recent study showed that PPAR γ was predominantly expressed in the cytoplasm of uveal melanoma tumor cells, suggesting that it might play an important role in the progression of uveal melanoma [117]. However, further studies are warranted to shed more light on a possible protective role of PPAR γ in this tumor.

Since PPAR γ has been shown to have the potential to treat autoimmune diseases [118–120], a murine model of experimental autoimmune uveoretinitis (EAU) was established to explore the efficacy of PPAR γ on endogenous uveitis. Intravenous injection of pioglitazone before and after the onset of EAU significantly reduced disease severity, suppressed intraocular concentrations of TNF-α and IL-6, and increased CD4(+)Foxp3(+) regulatory T cells and CD4(+)CD62L(high) naïve T cells in draining lymph nodes [121].

3. Significance and Future Prospects

TZDs (e.g., pioglitazone, troglitazone, and rosiglitazone) and 15d-PGJ2, as the existing therapeutic agents targeted to effect PPAR γ, may be the novel adjuvants in the treatment of ocular diseases. Pioglitazone and 15d-PGJ2 may inhibit corneal neovascularization and scar formation in cornea alkali burn injury model and VEGF-induced cornea angiogenesis and exert a therapeutic effect in dry eye mice. Rosiglitazone may represent a new strategy for inhibiting excessive bleb scarring in the cornel and conjunctiva after laser ablation and glaucoma filtering surgery. In retinal diseases troglitazone and rosiglitazone may attenuate the progression of AMD and DR in vivo. A clinical study suggested that rosiglitazone may delay the onset of proliferative DR. Pioglitazone and troglitazone also showed the neuroprotective effects in retina.

In summary, various experimental studies and several clinical studies have provided evidences that PPAR γ may emerge as a potential target for drugs that might be used in the treatment of ocular diseases in which PPAR γ activities play a key role in disease pathology. However, the complexity of PPAR γ activation not only provides beneficial effects but also introduces risks from undesirable side effects. Extensive preclinical and clinical trials are needed to establish the efficacy and to prove the safety of these drugs for the treatment of ocular diseases.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008.

C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, “Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors,” Cell, vol. 68, no. 5, pp. 879–887, 1992.

F. Chen, S. W. Law, and B. W. O'Malley, “Identification of two mPPAR related receptors and evidence for the existence of five subfamily members,” Biochemical and Biophysical Research Communications, vol. 196, no. 2, pp. 671–677, 1993.

Y. Zhu, K. Alvares, Q. Huang, M. S. Rao, and J. K. Reddy, “Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver,” The Journal of Biological Chemistry, vol. 268, no. 36, pp. 26817–26820, 1993.

Y. Barak, M. C. Nelson, E. S. Ong et al., “PPARγ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999.

X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo,” Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999.

J. V. Jester and D. J. Brown, “Wakayama symposium: peroxisome proliferator-activated receptor-gamma (PPARgamma) and meibomian gland dysfunction,” Ocular Surface, vol. 10, no. 4, pp. 224–229, 2012.

M. K. Song, B. D. Roufogalis, and T. H. W. Huang, “Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology,” British Journal of Pharmacology, vol. 165, no. 1, pp. 4–19, 2012.

L. L. C. Poulsen, M. Siersbaek, and S. Mandrup, “PPARs: fatty acid sensors controlling metabolism,” Seminars in Cell and Developmental Biology, vol. 23, no. 6, pp. 631–639, 2012.

M. Abdelrahman, A. Sivarajah, and C. Thiemermann, “Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock,” Cardiovascular Research, vol. 65, no. 4, pp. 772–781, 2005.

S. van Neerven and J. Mey, “RAR/RXR and PPAR/RXR signaling in spinal cord injury,” PPAR Research, vol. 2007, Article ID 29275, 14 pages, 2007.

R. T. Nolte, G. B. Wisely, S. Westin et al., “Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-gamma,” Nature, vol. 395, no. 6698, pp. 137–143, 1998.

B. Cariou, B. Charbonnel, and B. Staels, “Thiazolidinediones and PPAR agonists: time for a reassessment,” Trends in Endocrinology and Metabolism, vol. 23, no. 5, pp. 205–215, 2012.

J. Kung and R. R. Henry, “Thiazolidinedione safety,” Expert Opinion on Drug Safety, vol. 11, no. 4, pp. 565–579, 2012.

J. M. Olefsky and A. R. Saltiel, “PPARγ and the treatment of insulin resistance,” Trends in Endocrinology and Metabolism, vol. 11, no. 9, pp. 362–368, 2000.

R. F. Kletzien, S. D. Clarke, and R. G. Ulrich, “Enhancement of adipocyte differentiation by an insulin-sensitizing agent,” Molecular Pharmacology, vol. 41, no. 2, pp. 393–398, 1992.

E. D. Rosen and B. M. Spiegelman, “PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth,” The Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001.

P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPARgamma2: tissue-specific regulator of an adipocyte enhancer,” Genes and Development, vol. 8, no. 10, pp. 1224–1234, 1994.

A. W. Musser, “The planning, operation, and function of a clinical laboratory in a teaching hospital,” CRC Critical Reviews in Clinical Laboratory Sciences, vol. 6, no. 1, pp. 47–66, 1975.

T. Lemberger, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology,” Annual Review of Cell and Developmental Biology, vol. 12, pp. 335–363, 1996.

D. Panigrahy, S. Huang, M. W. Kieran, and A. Kaipainen, “PPARγ as a therapeutic target for tumor angiogenesis and metastasis,” Cancer Biology and Therapy, vol. 4, no. 7, pp. 687–693, 2005.

D. Bishop-Bailey, “PPARs and angiogenesis,” Biochemical Society Transactions, vol. 39, no. 6, pp. 1601–1605, 2011.

P. J. Sime, “The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis,” Journal of Investigative Medicine, vol. 56, no. 2, pp. 534–538, 2008.

C. Giaginis, A. Giagini, and S. Theocharis, “Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis,” Pharmacological Research, vol. 60, no. 3, pp. 160–169, 2009.

S. Polvani, M. Tarocchi, and A. Galli, “PPAR and oxidative stress: con(β) catenating NRF2 and FOXO,” PPAR Research, vol. 2012, Article ID 641087, 15 pages, 2012.

D. Bishop-Bailey and J. Bystrom, “Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation,” Pharmacology and Therapeutics, vol. 124, no. 2, pp. 141–150, 2009.

R. B. Clark, “The role of PPARs in inflammation and immunity,” Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388–400, 2002.

X. Zhang and H. A. Young, “PPAR and immune system—what do we know?” International Immunopharmacology, vol. 2, no. 8, pp. 1029–1044, 2002.

I. Szatmari, E. Rajnavolgyi, and L. Nagy, “PPARγ, a lipid-activated transcription factor as a regulator of dendritic cell function,” Annals of the New York Academy of Sciences, vol. 1088, pp. 207–218, 2006.

M. Sokolowska, M. L. Kowalski, and R. Pawliczak, “Peroxisome proliferator-activated receptors-gamma (PPAR-gamma) and their role in immunoregulation and inflammation control,” Postępy Higieny i Medycyny Doświadczalnej, vol. 59, pp. 472–484, 2005.

L. Szeles, D. Torocsik, and L. Nagy, “PPARgamma in immunity and inflammation: cell types and diseases,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1014–1030, 2007.

M. Colucciello, “Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus,” Archives of Ophthalmology, vol. 123, no. 9, pp. 1273–1275, 2005.

D. S. Fong and R. Contreras, “Glitazone use associated with diabetic macular edema,” The American Journal of Ophthalmology, vol. 147, no. 4, pp. 583.e1–586.e1, 2009.

N. V. Niemeyer and L. M. Janney, “Thiazolidinedione-induced edema,” Pharmacotherapy, vol. 22, no. 7, pp. 924–929, 2002.

I. Idris, G. Warren, and R. Donnelly, “Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes,” Archives of Internal Medicine, vol. 172, no. 13, pp. 1005–1011, 2012.

T. Baba, K. Shimada, S. Neugebauer, D. Yamada, S. Hashimoto, and T. Watanabe, “The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients,” Diabetes Care, vol. 24, no. 5, pp. 953–954, 2001.

M. Emoto, T. Anno, Y. Sato et al., “Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes,” Diabetes, vol. 50, no. 5, pp. 1166–1170, 2001.

D. T. Azar, “Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis),” Transactions of the American Ophthalmological Society, vol. 104, pp. 264–302, 2006.

C. Giaginis, A. Margeli, and S. Theocharis, “Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis,” Expert Opinion on Investigational Drugs, vol. 16, no. 10, pp. 1561–1572, 2007.

A. Margeli, G. Kouraklis, and S. Theocharis, “Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis,” Angiogenesis, vol. 6, no. 3, pp. 165–169, 2003.

T. Usui, K. Sugisaki, A. Iriyama et al., “Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor,” Investigative Ophthalmology and Visual Science, vol. 49, no. 10, pp. 4370–4376, 2008.

M. Uchiyama, A. Shimizu, Y. Masuda, S. Nagasaka, Y. Fukuda, and H. Takahashi, “An ophthalmic solution of a peroxisome proliferator-activated receptor gamma agonist prevents corneal inflammation in a rat alkali burn model,” Molecular Vision, vol. 19, pp. 2135–2150, 2013.

M. A. Sarayba, L. Li, T. Tungsiripat et al., “Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand,” Experimental Eye Research, vol. 80, no. 3, pp. 435–442, 2005.

W. Risau, “Mechanisms of angiogenesis,” Nature, vol. 386, no. 6626, pp. 671–674, 1997.

N. Wang, L. Verna, N. G. Chen et al., “Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells,” The Journal of Biological Chemistry, vol. 277, no. 37, pp. 34176–34181, 2002.

K. R. Huxlin, H. B. Hindman, K.-I. Jeon et al., “Topical rosiglitazone is an effective anti-scarring agent in the cornea,” PLoS ONE, vol. 8, no. 8, Article ID e70785, 2013.

A. E. Kuriyan, G. M. Lehmann, A. A. Kulkarni et al., “Electrophilic PPARγ ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: a potentially novel therapy for corneal scarring,” Experimental Eye Research, vol. 94, no. 1, pp. 136–145, 2012.

H. Pan, J. Chen, J. Xu, M. Chen, and R. Ma, “Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts,” Molecular Vision, vol. 15, pp. 2279–2286, 2009.

H.-W. Pan, J.-T. Xu, and J.-S. Chen, “Pioglitazone inhibits TGFbeta induced keratocyte transformation to myofibroblast and extracellular matrix production,” Molecular Biology Reports, vol. 38, no. 7, pp. 4501–4508, 2011.

S. Saika, O. Yamanaka, Y. Okada et al., “Effect of overexpression of pparγ on the healing process of corneal alkali burn in mice,” American Journal of Physiology: Cell Physiology, vol. 293, no. 1, pp. C75–C86, 2007.

O. Yamanaka, K.-I. Miyazaki, A. Kitano, S. Saika, Y. Nakajima, and K. Ikeda, “Suppression of injury-induced conjunctiva scarring by peroxisome proliferator-activated receptor γ gene transfer in mice,” Investigative Ophthalmology & Visual Science, vol. 50, no. 1, pp. 187–193, 2009.

F. Fan, Y. Li, X. Duan, T. Zhao, D. Pan, and H. Chen, “Rosiglitazone attenuates activation of human Tenon's fibroblasts induced by transforming growth factor-beta1,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 8, pp. 1213–1220, 2012.

X.-X. Yang, J. Chen, Q. Zhou et al., “Troglitazone induced apoptosis of human pterygium fibroblasts through a mitochondrial-dependent pathway,” International Journal of Ophthalmology, vol. 4, no. 2, pp. 143–146, 2011.

T. Hyvonen, A. R. Khomutov, R. M. Khomutov, S. Lapinjoki, and T. O. Eloranta, “Uptake of 3H-labeled 1-aminooxy-3-aminopropane by baby hamster kidney cells,” Journal of Biochemistry, vol. 107, no. 6, pp. 817–820, 1990.

Y. Chen, X. Zhang, L. Yang et al., “Decreased PPAR- expression in the conjunctiva and increased expression of TNF- and IL-1 in the conjunctiva and tear fluid of dry eye mice,” Molecular Medicine Reports, vol. 9, no. 5, pp. 2015–2023, 2014.

C. Beauregard and P. C. Brandt, “Peroxisome proliferator-activated receptor agonists inhibit interleukin-1beta-mediated nitric oxide production in cultured lacrimal gland acinar cells,” Journal of Ocular Pharmacology and Therapeutics, vol. 19, no. 6, pp. 579–587, 2003.

C. J. Nien, S. Massei, G. Lin et al., “Effects of age and dysfunction on human meibomian glands,” Archives of Ophthalmology, vol. 129, no. 4, pp. 462–469, 2011.

C. J. Nien, J. R. Paugh, S. Massei, A. J. Wahlert, W. W. Kao, and J. V. Jester, “Age-related changes in the meibomian gland,” Experimental Eye Research, vol. 89, no. 6, pp. 1021–1027, 2009.

R. J. Herm, “Age-related macular degeneration,” The New England Journal of Medicine, vol. 359, no. 16, pp. 1735–1736, 2008.

A. A. Herzlich, X. Ding, D. Shen, R. J. Ross, J. Tuo, and C. C. Chan, “Peroxisome proliferator-activated receptor expression in murine models and humans with age-related macular degeneration,” The Open Biology Journal, vol. 2, no. 1, pp. 141–148, 2009.

T. Murata, S. He, M. Hangai et al., “Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization,” Investigative Ophthalmology and Visual Science, vol. 41, no. 8, pp. 2309–2317, 2000.

J. P. Vanden Heuvel, “Nutrigenomics and nutrigenetics of ω3 polyunsaturated fatty acids,” Progress in Molecular Biology and Translational Science, vol. 108, pp. 75–112, 2012.

E. W.-T. Chong, A. J. Kreis, T. Y. Wong, J. A. Simpson, and R. H. Guymer, “Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis,” Archives of Ophthalmology, vol. 126, no. 6, pp. 826–833, 2008.

O. Strauss, The Retinal Pigment Epithelium, 1995.

J. Cai, K. C. Nelson, M. Wu, P. J. Sternberg, and D. P. Jones, “Oxidative damage and protection of the RPE,” Progress in Retinal and Eye Research, vol. 19, no. 2, pp. 205–221, 2000.

A. V. Ershov and N. G. Bazan, “Photoreceptor phagocytosis selectively activates PPARgamma expression in retinal pigment epithelial cells,” Journal of Neuroscience Research, vol. 60, no. 3, pp. 328–337, 2000.

S. Qin, A. P. McLaughlin, and G. W. de Vries, “Protection of RPE cells from oxidative injury by 15-deoxy-Δ 12,14-prostaglandin J2 by augmenting GSH and activating MAPK,” Investigative Ophthalmology & Visual Science, vol. 47, no. 11, pp. 5098–5105, 2006.

T. K. Garg and J. Y. Chang, “Oxidative stress causes ERK phosphorylation and cell death in cultured retinal pigment epithelium: prevention of cell death by AG126 and 15-deoxy-delta 12, 14-PGJ2,” BMC Ophthalmology, vol. 3, article 5, 2003.

G. A. Rodrigues, F. Maurier-Mahé, D.-L. Shurland et al., “Differential effects of PPAR ligands on oxidative stress-induced death of retinal pigmented epithelial cells,” Investigative Ophthalmology and Visual Science, vol. 52, no. 2, pp. 890–903, 2011.

R. Walczak and P. Tontonoz, “PPARadigms and PPARadoxes: expanding roles for PPARγ in the control of lipid metabolism,” Journal of Lipid Research, vol. 43, no. 2, pp. 177–186, 2002.

C. H. Lee and R. M. Evans, “Peroxisome proliferator-activated receptor-gamma in macrophage lipid homeostasis,” Trends in Endocrinology and Metabolism, vol. 13, no. 8, pp. 331–335, 2002.

P. Delerive, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors in inflammation control,” Journal of Endocrinology, vol. 169, no. 3, pp. 453–459, 2001.

A. C. Calkin, J. M. Forbes, C. M. Smith et al., “Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1903–1909, 2005.

S. Ji, G. Kronenberg, M. Balkaya et al., “Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome,” Experimental Neurology, vol. 216, no. 2, pp. 321–328, 2009.

Y. Ren, C. Sun, Y. Sun et al., “PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation,” Vascular Pharmacology, vol. 51, no. 2-3, pp. 169–174, 2009.

J. Kim, Y.-S. Oh, and S.-H. Shinn, “Troglitazone reverses the inhibition of nitric oxide production by high glucose in cultured bovine retinal pericytes,” Experimental Eye Research, vol. 81, no. 1, pp. 65–70, 2005.

K. Muranaka, Y. Yanagi, Y. Tamaki et al., “Effects of peroxisome proliferator-activated receptor and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model,” Investigative Ophthalmology and Visual Science, vol. 47, no. 10, pp. 4547–4552, 2006.

Z. Zheng, H. Chen, H. Wang et al., “Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor γ coactivator 1α,” Diabetes, vol. 59, no. 9, pp. 2315–2325, 2010.

A. Higuchi, K. Ohashi, R. Shibata, S. Sono-Romanelli, K. Walsh, and N. Ouchi, “Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 1, pp. 46–53, 2010.

H. Hatanaka, N. Koizumi, N. Okumura et al., “Epithelial-mesenchymal transition-like phenotypic changes of retinal pigment epithelium induced by TGF-γ Are prevented by PPAR-γ agonists,” Investigative Ophthalmology & Visual Science, vol. 53, no. 11, pp. 6955–6963, 2012.

P. Li, X. Xu, Z. Zheng, B. Zhu, Y. Shi, and K. Liu, “Protective effects of rosiglitazone on retinal neuronal damage in diabetic rats,” Current Eye Research, vol. 36, no. 7, pp. 673–679, 2011.

Y. Jiang, S. Thakran, R. Bheemreddy et al., “Pioglitazone normalizes insulin signaling in the diabetic rat retina through reduction in tumor necrosis factor alpha and suppressor of cytokine signaling 3,” The Journal of Biological Chemistry, vol. 289, no. 38, pp. 26395–26405, 2014.

T. Murata, Y. Hata, T. Ishibashi et al., “Response of experimental retinal neovascularization to thiazolidinediones,” Archives of Ophthalmology, vol. 119, no. 5, pp. 709–717, 2001.

L. Q. Shen, A. Child, G. M. Weber, J. Folkman, and L. P. Aiello, “Rosiglitazone and delayed onset of proliferative diabetic retinopathy,” Archives of Ophthalmology, vol. 126, no. 6, pp. 793–799, 2008.

S. Azar, G. M. El-Mollayess, L. Al Shaar, H. I. Salti, and Z. F. Bashshur, “Impact of thiazolidinediones on macular thickness and volume in diabetic eyes,” Canadian Journal of Ophthalmology, vol. 48, no. 4, pp. 312–316, 2013.

A. K. Tarbett, R. C. VanRoekel, R. S. Howard, and R. A. Vigersky, “The use of optical coherence tomography to determine the effect of thiazolidinediones on retinal thickness in patients with type 2 diabetes,” Journal of Diabetes Science and Technology, vol. 5, no. 4, pp. 945–951, 2011.

S. Asgary, G. A. Naderi, N. Sarraf-Zadegan, and R. Vakili, “The inhibitory effects of pure flavonoids on in vitro protein glycosylation,” Journal of Herbal Pharmacotherapy, vol. 2, no. 2, pp. 47–55, 2002.

H. Y. Wang and M. L. Cheng, “Effects of Dan-shao-hua-xian on expression of PPAR-gamma and NF-kappa B in rat liver fibrosis,” Hepatobiliary and Pancreatic Diseases International, vol. 7, no. 2, pp. 179–184, 2008.

K. Motomura, Y. Fujiwara, N. Kiyota et al., “Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products,” Journal of Agricultural and Food Chemistry, vol. 57, no. 17, pp. 7666–7672, 2009.

X.-C. Liang, N. Hagino, S.-S. Guo, T. Tsutsumi, and S. Kobayashi, “Therapeutic efficacy of Stephania tetrandra S. Moore for treatment of neovascularization of retinal capillary (retinopathy) in diabetes—in vitro study,” Phytomedicine, vol. 9, no. 5, pp. 377–384, 2002.

Y. Zhou, S. Zheng, J. Lin, Q.-J. Zhang, and A. Chen, “The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPAR in rat activated hepatic stellate cell in vitro,” Laboratory Investigation, vol. 87, no. 5, pp. 488–498, 2007.

R. A. Kowluru and M. Kanwar, “Effects of curcumin on retinal oxidative stress and inflammation in diabetes,” Nutrition and Metabolism, vol. 4, article 8, 2007.

T. Mrudula, P. Suryanarayana, P. N. B. S. Srinivas, and G. B. Reddy, “Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina,” Biochemical and Biophysical Research Communications, vol. 361, no. 2, pp. 528–532, 2007.

M. Balasubramanyam, A. A. Koteswari, R. S. Kumar, S. F. Monickaraj, J. U. Maheswari, and V. Mohan, “Curcumin-induced inhibition of cellular reactive oxygen species generation: novel therapeutic implications,” Journal of Biosciences, vol. 28, no. 6, pp. 715–721, 2003.

J.-L. Liu, J.-W. Jin, S.-J. Pei, and C. Wang, “Flurbiprofen axetil promotes neuroprotection by activation of cerebral peroxisome proliferator-activated receptor gamma after focal cerebral ischemia in rats,” Chinese Medical Journal, vol. 125, no. 20, pp. 3719–3724, 2012.

A. R. Carta, L. Frau, A. Pisanu, J. Wardas, S. Spiga, and E. Carboni, “Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model,” Neuroscience, vol. 194, pp. 250–261, 2011.

L. Escribano, A.-M. Simón, A. Pérez-Mediavilla, P. Salazar-Colocho, J. D. Río, and D. Frechilla, “Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model,” Biochemical and Biophysical Research Communications, vol. 379, no. 2, pp. 406–410, 2009.

M. Kiaei, K. Kipiani, J. Chen, N. Y. Calingasan, and M. F. Beal, “Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis,” Experimental Neurology, vol. 191, no. 2, pp. 331–336, 2005.

E. Esposito and S. Cuzzocrea, “Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury,” Expert Opinion on Therapeutic Targets, vol. 15, no. 8, pp. 943–959, 2011.

L. Qi, A. Jacob, P. Wang, and R. Wu, “Peroxisome proliferator activated receptor-gamma and traumatic brain injury,” International Journal of Clinical and Experimental Medicine, vol. 3, no. 4, pp. 283–292, 2010.

C. H. Lee, O. K. Park, K.-Y. Yoo et al., “The role of peroxisome proliferator-activated receptor γ, and effects of its agonist, rosiglitazone, on transient cerebral ischemic damage,” Journal of the Neurological Sciences, vol. 300, no. 1-2, pp. 120–129, 2011.

Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman, “Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats,” The FASEB Journal, vol. 20, no. 8, pp. 1162–1175, 2006.

J.-H. Yi, S.-W. Park, N. Brooks, B. T. Lang, and R. Vemuganti, “PPAR agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms,” Brain Research, vol. 1244, pp. 164–172, 2008.

J. Zhu, J. Zhang, M. Ji et al., “The role of peroxisome proliferator-activated receptor and effects of its agonist, pioglitazone, on a rat model of optic nerve crush: PPARgamma in retinal neuroprotection,” PLoS ONE, vol. 8, no. 7, Article ID e68935, 2013.

X.-Y. Zhang, Y.-Q. Xiao, Y. Zhang, and W. Ye, “Protective effect of pioglitazone on retinal ischemia/ reperfusion injury in rats,” Investigative Ophthalmology and Visual Science, vol. 54, no. 6, pp. 3912–3921, 2013.

L. Y. Mimura, S. M. F. Villares, M. L. R. Monteiro, I. C. Guazzelli, and W. Bloise, “Peroxisome proliferator-activated receptor- gene expression in orbital adipose/connective tissues is increased during the active stage of Graves' ophthalmopathy,” Thyroid, vol. 13, no. 9, pp. 845–850, 2003.

S. Kumar, M. J. Coenen, P. E. Scherer, and R. S. Bahn, “Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 930–935, 2004.

G. M. Lehmann, T. M. Garcia-Bates, T. J. Smith, S. E. Feldon, and R. P. Phipps, “Regulation of lymphocyte function by PPARgamma: relevance to thyroid eye disease-related inflammation,” PPAR Research, vol. 2008, Article ID 895901, 12 pages, 2008.

P. Zhao, Y. Deng, P. Gu et al., “Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy,” Experimental Eye Research, vol. 107, pp. 65–73, 2013.

K. Starkey, A. Heufelder, G. Baker et al., “Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 1, pp. 55–59, 2003.

W. Bloise, L. Y. Mimura, J. Moura, and W. Nicolau, “Treatment of mild to moderate graves' ophthalmopathy with sodium diclofenac: a pilot study,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 55, no. 9, pp. 692–695, 2011.

N. Guo, C. F. Woeller, S. E. Feldon, and R. P. Phipps, “Peroxisome proliferator-activated receptor ligands inhibit transforming growth factor--induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts,” Journal of Biological Chemistry, vol. 286, no. 21, pp. 18856–18867, 2011.

B. Bhatia, C. R. Potts, C. Guldal et al., “Hedgehog-mediated regulation of PPARgamma controls metabolic patterns in neural precursors and shh-driven medulloblastoma,” Acta Neuropathologica, vol. 123, no. 4, pp. 587–600, 2012.

C. Lee, J. A. Ramirez, J. Guitart, and L. K. Diaz, “Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression,” Journal of Cutaneous Pathology, vol. 35, no. 11, pp. 989–994, 2008.

P. Knapp, A. Chabowski, A. Bachnio-Zabielska, K. Jarzbek, and S. Wołczyski, “Altered peroxisome-proliferator activated receptors expression in human endometrial cancer,” PPAR Research, vol. 2012, Article ID 471524, 5 pages, 2012.

S. Meyer, T. Vogt, M. Landthaler et al., “Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma,” PPAR Research, vol. 2010, Article ID 848645, 11 pages, 2010.

M. C. Herwig, C. Bergstrom, J. R. Wells, T. Höller, and H. E. Grossniklaus, “M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles,” Experimental Eye Research, vol. 107, pp. 52–58, 2013.

M. K. Racke, A. R. Gocke, M. Muir, A. Diab, P. D. Drew, and A. E. Lovett-Racke, “Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis,” Journal of Nutrition, vol. 136, no. 3, pp. 700–703, 2006.

J. M. Choi and A. L. M. Bothwell, “The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases,” Molecules and Cells, vol. 33, no. 3, pp. 217–222, 2012.

H. Ramkalawan, Y.-Z. Wang, A. Hurbungs et al., “Pioglitazone, PPAR agonist, attenuates experimental autoimmune neuritis,” Inflammation, vol. 35, no. 4, pp. 1338–1347, 2012.

Y. Okunuki, Y. Usui, H. Nakagawa et al., “Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis,” Experimental Eye Research, vol. 116, pp. 291–297, 2013.

C. Ulivieri and C. T. Baldari, “The potential of peroxisome proliferator-activated receptor γ (PPARγ) ligands in the treatment of hematological malignancies,” Mini-Reviews in Medicinal Chemistry, vol. 7, no. 9, pp. 877–887, 2007.

T. Wang, J. Xu, X. Yu, R. Yang, and Z. C. Han, “Peroxisome proliferator-activated receptor gamma in malignant diseases,” Critical Reviews in Oncology/Hematology, vol. 58, no. 1, pp. 1–14, 2006.

L. Gelman, J. N. Feige, and B. Desvergne, “Molecular basis of selective PPARγ modulation for the treatment of Type 2 diabetes,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1094–1107, 2007.

B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-12, 14-prostaglandin J₂ is a ligand for the adipocyte determination factor PPAR,” Cell, vol. 83, no. 5, pp. 803–812, 1995.

F. J. Schopfer, Y. Lin, P. R. S. Baker et al., “Nitrolinoleic acid: An endogenous peroxisome proliferator-activated receptor gamma ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2340–2345, 2005.

B. Zingarelli and J. A. Cook, “Peroxisome proliferator-activated receptor-γ is a new therapeutic target in sepsis and inflammation,” Shock, vol. 23, no. 5, pp. 393–399, 2005.

B. Staels and J.-C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005.

C. Zang, H. Liu, M. Waechter et al., “Dual PPARα/γ ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines,” Cell Cycle, vol. 5, no. 19, pp. 2237–2243, 2006.

T. Shibata, K. Matsui, K. Nagao, H. Shinkai, F. Yonemori, and K. Wakitani, “Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative,” European Journal of Pharmacology, vol. 364, no. 2-3, pp. 211–219, 1999.

Y. Wang, W. W. Porter, N. Suh et al., “A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma,” Molecular Endocrinology, vol. 14, no. 10, pp. 1550–1556, 2000.

P. W. Young, D. R. Buckle, B. C. C. Cantello et al., “Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ,” Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 2, pp. 751–759, 1998.

Y. Rival, A. Stennevin, L. Puech et al., “Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor γ ligands,” Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 2, pp. 467–475, 2004.

C. Rousseaux, B. Lefebvre, L. Dubuquoy et al., “Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma,” The Journal of Experimental Medicine, vol. 201, no. 8, pp. 1205–1215, 2005.

P. Misra, R. Chakrabarti, R. K. Vikramadithyan et al., “PAT5A: a partial agonist of peroxisome proliferator-activated receptor γ is a potent antidiabetic thiazolidinedione yet weakly adipogenic,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 2, pp. 763–771, 2003.

J. Sakamoto, H. Kimura, S. Moriyama et al., “A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes,” European Journal of Pharmacology, vol. 495, no. 1, pp. 17–26, 2004.

T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000.

M.-B. Debril, J.-P. Renaud, L. Fajas, and J. Auwerx, “The pleiotropic functions of peroxisome proliferator-activated receptor γ,” Journal of Molecular Medicine, vol. 79, no. 1, pp. 30–47, 2001.

K. L. Houseknecht, B. M. Cole, and P. J. Steele, “Peroxisome proliferator-activated receptor gamma (PPARγ) and its ligands: a review,” Domestic Animal Endocrinology, vol. 22, no. 1, pp. 1–23, 2002.

Y.-C. Li, Q. Chen, X.-Z. Wan, X.-L. Yang, X. Liu, and L. Zhong, “Effects of conjugated linoleic acid on cleavage of amyloid precursor protein via PPARgamma,” Neurological Sciences, vol. 32, no. 6, pp. 1095–1101, 2011.

A. Elbrecht, Y. Chen, A. Adams et al., “L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding,” The Journal of Biological Chemistry, vol. 274, no. 12, pp. 7913–7922, 1999.

M. P. Pereira, O. Hurtado, A. Cárdenas et al., “The nonthiazolidinedione PPARγ agonist L-796,449 is neuroprotective in experimental stroke,” Journal of Neuropathology and Experimental Neurology, vol. 64, no. 9, pp. 797–805, 2005.

S. K. Engle, P. F. Solter, K. M. Credille et al., “Detection of left ventricular hypertrophy in rats administered a peroxisome proliferator-activated receptor alpha/gamma dual agonist using natriuretic peptides and imaging,” Toxicological Sciences, vol. 114, no. 2, pp. 183–192, 2010.

S. H. Zuckerman, R. F. Kauffman, and G. F. Evans, “Peroxisome proliferator-activated receptor α,γ coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice,” Lipids, vol. 37, no. 5, pp. 487–494, 2002.

K. Murakami, K. Tobe, T. Ide et al., “A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ. Effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats,” Diabetes, vol. 47, no. 12, pp. 1841–1847, 1998.

C. L. Richard and J. Blay, “Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor γ-dependent manner,” International Journal of Oncology, vol. 30, no. 5, pp. 1215–1222, 2007.

S.-H. Sheu, T. Kaya, D. J. Waxman, and S. Vajda, “Exploring the binding site structure of the PPARγ ligand-binding domain by computational solvent mapping,” Biochemistry, vol. 44, no. 4, pp. 1193–1209, 2005.

J. Kaur and S. N. Sanyal, “Modulation of inflammatory changes in early stages of colon cancer through activation of PPARgamma by diclofenac,” European Journal of Cancer Prevention, vol. 19, no. 5, pp. 319–327, 2010.

M. A. Lea, M. Sura, and C. Desbordes, “Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists,” Anticancer Research, vol. 24, no. 5, pp. 2765–2771, 2004.

F. M. C. da Silva, J. C. dos Santos, J. L. O. Campos et al., “Structure-based identification of novel PPAR gamma ligands,” Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 21, pp. 5795–5802, 2013.